Literature DB >> 26528829

A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy.

Silvia Cocchio1, Giovanna Zanoni2, Roberta Opri3, Francesca Russo4, Vincenzo Baldo1.   

Abstract

It is strategically important to monitor the safety profile of vaccination schedules in order to achieve and maintain high levels of coverage. We analyzed the cohort of individuals actively invited for measles, mumps, rubella and varicella (MMRV) vaccination in the Veneto region (north-east Italy) from 8/1/2013 to 7/31/2014, assessing the onset of adverse events (AE) relating to 2 different vaccination strategies for MMRV (MMR+V vs MMRV). During the vaccination session at 14 months old, parents were given a form for recording local and systemic reactions to vaccinations for 4 weeks afterwards. Overall, 12,288 forms were returned, and 84.6% of them were included in this analysis (5,130 relating to MMR+V and 5,265 to MMRV); 37.3% of the sample reported no AEs, with no difference between the 2 groups. Local reactions were more common in the MMR+V group (9.6% vs 2.9%; RR 3.33; 95% CI 2.79-3.98), while there was no difference in general reactions between the 2 groups (50% MMR+V vs 52% MMRV). The events most often reported were "fever <39.5°C," which was more frequently associated with the MMRV strategy (p<0.001), and "skin blotches and marks," which occurred more often in the MMR+V group (p<0.001). Reports of "fever ≥39.5°C" were equally distributed between the 2 groups. Sixteen cases of febrile seizures were reported (0.14% in the MMR+V group and 0.17% in the MMRV group). Similar safety profiles were identified for the 2 vaccination strategies. Although the method used to record reactions to vaccination demanded considerable resources, it enabled important information to be collected on parents' perception of the AEs occurring in response to their child's vaccination.

Entities:  

Keywords:  MMR+V; MMRV; active surveillance; adverse event; febrile seizure

Mesh:

Substances:

Year:  2016        PMID: 26528829      PMCID: PMC4964739          DOI: 10.1080/21645515.2015.1101198

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  18 in total

1.  Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Mona Marin; Karen R Broder; Jonathan L Temte; Dixie E Snider; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2010-05-07

2.  Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.

Authors:  Tania Schink; Jakob Holstiege; Frank Kowalzik; Fred Zepp; Edeltraut Garbe
Journal:  Vaccine       Date:  2013-12-25       Impact factor: 3.641

3.  Consultancy and surveillance of post-immunisation adverse events in the Veneto region of Italy for 1992-2008.

Authors:  Fabiola Micheletti; Ugo Moretti; Giuseppe Tridente; Giovanna Zanoni
Journal:  Hum Vaccin       Date:  2011-01-01

4.  Safety of measles-containing vaccines in 1-year-old children.

Authors:  Nicola P Klein; Edwin Lewis; Bruce Fireman; Simon J Hambidge; Allison Naleway; Jennifer C Nelson; Edward A Belongia; W Katherine Yih; James D Nordin; Rulin C Hechter; Eric Weintraub; Roger Baxter
Journal:  Pediatrics       Date:  2015-01-05       Impact factor: 7.124

Review 5.  Risk of febrile seizure after measles-mumps-rubella-varicella vaccine: A systematic review and meta-analysis.

Authors:  Shu-Juan Ma; Yi-Quan Xiong; Li-Na Jiang; Qing Chen
Journal:  Vaccine       Date:  2015-06-11       Impact factor: 3.641

6.  The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.

Authors:  W E Barlow; R L Davis; J W Glasser; P H Rhodes; R S Thompson; J P Mullooly; S B Black; H R Shinefield; J I Ward; S M Marcy; F DeStefano; R T Chen; V Immanuel; J A Pearson; C M Vadheim; V Rebolledo; D Christakis; P J Benson; N Lewis
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

7.  Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.

Authors:  Julia Hy Leung; Hoyee W Hirai; Kelvin Kf Tsoi
Journal:  Expert Rev Vaccines       Date:  2015-06-16       Impact factor: 5.217

8.  Benefits of combination vaccines: effective vaccination on a simplified schedule.

Authors:  Daisy Dodd
Journal:  Am J Manag Care       Date:  2003-01       Impact factor: 2.229

9.  Varicella: epidemiological aspects and vaccination coverage in the Veneto Region.

Authors:  Vincenzo Baldo; Tatjana Baldovin; Francesca Russo; Marta Cecilia Busana; Cinzia Piovesan; Greta Bordignon; Aurore Giliberti; Renzo Trivello
Journal:  BMC Infect Dis       Date:  2009-09-08       Impact factor: 3.090

10.  Impact of universal vaccination against varicella in Italy.

Authors:  Angela Bechini; Sara Boccalini; Vincenzo Baldo; Silvia Cocchio; Paolo Castiglia; Tolinda Gallo; Sandro Giuffrida; Francesco Locuratolo; Silvio Tafuri; Domenico Martinelli; Rosa Prato; Emanuele Amodio; Francesco Vitale; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

View more
  7 in total

1.  Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data.

Authors:  Meredith Woodward; Ann Marko; Susan Galea; Barry Eagel; Walter Straus
Journal:  Open Forum Infect Dis       Date:  2019-08-01       Impact factor: 3.835

2.  Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy.

Authors:  Gabriele Anichini; Claudia Gandolfo; Simonetta Fabrizi; Giovan Battista Miceli; Chiara Terrosi; Gianni Gori Savellini; Shibily Prathyumnan; Daniela Orsi; Giuseppe Battista; Maria Grazia Cusi
Journal:  Vaccines (Basel)       Date:  2020-02-03

3.  Adverse Events Following Measles-Mumps-Rubella-Varicella Vaccination and the Case of Seizures: A Post Marketing Active Surveillance in Puglia Italian Region, 2017-2018.

Authors:  Pasquale Stefanizzi; Paolo Stella; Domenica Ancona; Katia Nicoletta Malcangi; Francesco Paolo Bianchi; Sara De Nitto; Davide Ferorelli; Cinzia Annatea Germinario; Silvio Tafuri
Journal:  Vaccines (Basel)       Date:  2019-10-07

4.  Adverse events following measles-mumps-rubella-varicella vaccine: an independent perspective on Italian pharmacovigilance data.

Authors:  Paolo Bellavite; Alberto Donzelli
Journal:  F1000Res       Date:  2020-09-28

5.  Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017.

Authors:  F Moretti; L Gonella; S Gironi; A R Marra; C Santuccio; P Felicetti; F Petronzelli; P Marchione; S A Barnaba; A Poli; G Zanoni; U Moretti
Journal:  Sci Rep       Date:  2020-08-24       Impact factor: 4.379

6.  Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017.

Authors:  Pasquale Stefanizzi; Sara De Nitto; Francesco Patano; Francesco Paolo Bianchi; Davide Ferorelli; Paolo Stella; Domenica Ancona; Vito Bavaro; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2020-02-10       Impact factor: 3.452

7.  Non-specific effects of vaccinations in high-income settings: How to address the issue?

Authors:  Alberto Donzelli; Alessandro Schivalocchi; Giulia Giudicatti
Journal:  Hum Vaccin Immunother       Date:  2018-08-27       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.